GF90307144
镧
foil, not light tested, 25x25mm, thickness 0.025mm, as rolled, 99%
别名:
镧
方案
≥99%
表单
foil
制造商/商品名称
Goodfellow 903-071-44
电阻率
54 μΩ-cm
沸点
3464 °C (lit.)
mp
920 °C (lit.)
密度
6.19 g/mL at 25 °C (lit.)
SMILES字符串
[La]
InChI
1S/La
InChI key
FZLIPJUXYLNCLC-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
For updated SDS information please visit www.goodfellow.com.
法律信息
Product of Goodfellow
储存分类代码
4.3 - Hazardous materials which set free flammable gases upon contact with water
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
此项目有
Yongsheng Yang et al.
Molecular pharmaceutics, 10(2), 544-550 (2012-12-20)
A conventional human pharmacokinetic (PK) in vivo study is often considered as the "gold standard" to determine bioequivalence (BE) of drug products. However, this BE approach is not always applicable to the products not intended to be delivered into the
Monique P Curran et al.
Drugs, 69(16), 2329-2349 (2009-10-27)
Orally administered lanthanum carbonate (Fosrenol) dissociates in the acid environment of the upper gastrointestinal tract to release the cation lanthanum, which then binds dietary phosphate. Lanthanum carbonate was effective in reducing levels of serum phosphate and serum calcium x phosphate
Stuart M Sprague
Current medical research and opinion, 23(12), 3167-3175 (2007-11-10)
Obstacles to successful management of hyperphosphatemia in chronic kidney disease include inadequate control of dietary phosphate and non-compliance with phosphate-binder therapy. Three major classes of phosphate binders include calcium-based binders, sevelamer HCl, and lanthanum carbonate. A literature search was performed
Mario Cozzolino et al.
Expert opinion on pharmacotherapy, 13(16), 2337-2353 (2012-10-05)
High phosphate levels are associated with unfavorable outcomes in ESRD. Recent data suggested that phosphate levels within the normal range are equally associated with poor outcomes in the community and CKD stage 3 - 4. Several concept papers support the
Stephen J P Damment et al.
Clinical pharmacokinetics, 47(9), 553-563 (2008-08-14)
Lanthanum carbonate is considered to be the most potent of a new generation of noncalcium phosphate binders used to treat hyperphosphataemia in chronic kidney disease (CKD), a condition associated with progressive bone and cardiovascular pathology and a markedly elevated risk
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持